STOCK TITAN
  1. Home
  2. News
  3. INKT

Mink Therapeutics, Inc. - INKT STOCK NEWS

Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.

MiNK Therapeutics, Inc. (INKT) is a clinical-stage biopharmaceutical company pioneering allogeneic iNKT cell therapies for cancer and immune-mediated diseases. This page provides investors and industry observers with timely updates on material developments, including clinical trial progress, regulatory milestones, and strategic partnerships.

Access verified press releases and news articles covering MiNK Therapeutics' innovative pipeline, manufacturing advancements, and collaborative research initiatives. Content spans earnings announcements, trial data disclosures, executive leadership updates, and scientific presentations relevant to the company’s position in the immunotherapy sector.

Bookmark this page for streamlined tracking of INKT’s progress in developing off-the-shelf cellular therapies. Check regularly for authoritative updates that inform analysis of the company’s scientific and commercial trajectory.

News

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Rhea-AI Summary

MiNK Therapeutics, Inc. (NASDAQ: INKT) will release its first quarter 2024 financial results on May 14, 2024. The company is focused on developing iNKT cell therapies for cancer and immune diseases. An executive conference call and webcast will follow to discuss the results and provide a corporate update.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
earnings
-
News

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Rhea-AI Summary
MiNK-215, a novel cellular therapy developed by MiNK Therapeutics, has shown promising results in combating colorectal cancer liver metastases. The therapy, presented at AACR, demonstrated significant anti-tumor activity through various mechanisms, offering hope to patients with treatment-resistant cancer. MiNK-215's collaboration potential with other immunotherapies like botensilimab and balstilimab highlights its versatility and effectiveness in enhancing the anti-tumor response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.38%
Tags
none
-
News

MiNK Reports Fourth Quarter and Year-End 2023 Results

Rhea-AI Summary
MiNK Therapeutics, Inc. (INKT) announced significant advancements in allogeneic iNKT cell therapies for cancer and immune-mediated diseases. Key highlights include the launch of a Phase 2 trial in gastroesophageal cancers, positive clinical data in solid tumors and ARDS, collaboration with Immunoscape, and financial results for Q4 and full-year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
News

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT) will release its fourth quarter and year-end 2023 financial results on March 21, 2024. The company focuses on developing iNKT cell therapies for cancer and immune-mediated diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.61%
Tags
earnings
-
News

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

Rhea-AI Summary
MiNK-215, an IL-15 armored FAP-targeting CAR-iNKT cell therapy, showed promising results in eradicating tumor cells in human organoid MSS colorectal cancer liver metastases models. The therapy enhanced tumor killing by T cells, depleted immune suppressive cells, and increased CD8+ T cell infiltration, potentially improving outcomes for patients with liver metastases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
clinical trial
-
News

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab

Rhea-AI Summary
MiNK Therapeutics, Inc. (INKT) announces the initiation of a Phase 2 investigator sponsored study for agenT-797 in second line gastroesophageal cancer at Memorial Sloan Kettering Cancer Center. The study aims to address the treatment challenges faced by ~70% of Gastroesophageal Cancer (GEC) patients. The trial involves a novel combination of Allogeneic Cell Therapy with BOT/BAL and aims to evaluate the safety and efficacy of agenT-797 in combination with botensilimab, balstilimab, ramucirumab, and paclitaxel for patients with advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.76%
Tags
clinical trial
News

MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT) announced promising results from a phase 1/2 study of agenT-797 in patients with severe respiratory distress due to SARS-CoV-2. The study showed improved survival rates, with over 70% survival in patients on mechanical ventilation and an 80% survival rate in patients on VV ECMO. AgenT-797 also demonstrated the ability to induce anti-inflammatory biomarkers, prevent secondary infections, and reduce pneumonia by over 80%. The results highlight the potential of allogeneic iNKT cell therapies in treating severe respiratory distress and immune-related diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.2%
Tags
none
-
News

MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT) announced a case report highlighting the potential of iNKT cell therapies to treat advanced solid tumors. The study showed a durable confirmed partial response in a patient with gastric cancer refractory to anti-PD1, indicating the unique potential of iNKT cells to overcome resistance to immune checkpoint inhibitors. The company is continuing to advance iNKT cells in this setting and is looking forward to further updates on its solid tumor programs this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
none
-
News

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Rhea-AI Summary
MiNK Therapeutics, Inc (Nasdaq: INKT) and ImmunoScape collaborate to develop TCR-based therapies for solid tumors, leveraging MiNK's proprietary library of T-cell antigens and ImmunoScape's Deep Immunomics platform. The collaboration aims to accelerate the development of next-generation TCR therapies against novel targets in solid tumors, offering new therapeutic approaches for diverse cancer indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

MiNK Therapeutics Reports Third Quarter 2023 Results

Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT) reports positive financial results for Q3 2023, highlights data showing durable clinical benefit in solid tumor cancers and potential in severe respiratory distress. AgenT-797 demonstrates improved survival in late-stage metastatic cancer patients. The company plans to expand into autoimmune and inflammatory diseases. A conference call is scheduled for November 9, 2023, at 8:30 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.72%
Tags
earnings
Stock INKT logo
Mink Therapeutics, Inc.

Nasdaq:INKT

INKT Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

INKT Stock Data

28.76M
1.00M
74.83%
2.09%
0.68%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK